Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1

Simple item page
dc.contributor.authorKilickap, S.
dc.contributor.authorSezer, A.
dc.contributor.authorGumus, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGogishvili, M.
dc.contributor.authorHe, X.
dc.contributor.authorGullo, G.
dc.contributor.authorRietschel, P.
dc.contributor.authorQuek, R. G.
dc.date.accessioned2022-11-04T08:51:48Z
dc.date.available2022-11-04T08:51:48Z
dc.date.issued2022
dc.identifier.endpage126en_US
dc.identifier.issn1556-0864en_US
dc.identifier.issue9en_US
dc.identifier.startpage125en_US
dc.identifier.urihttp://hdl.handle.net/11727/8004
dc.identifier.volume17en_US
dc.identifier.wos000858678100196en_US
dc.language.isoengen_US
dc.relation.journalJOURNAL OF THORACIC ONCOLOGYen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlePatient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1en_US
dc.typeConference Objecten_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Tıp Fakültesi / Faculty of Medicine